Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Newnham, Genni M ^a,c   Conron, Matthew ^a   McLachlan, SueAnne ^a,c   Dobrovic, Alexander ^b,c   Do, Hongdo ^b,c   Li, Jason ^b   Opeskin, Kenneth ^a   Thompson, Natalie ^b   Wright, Gavin M ^a   Thomas, David M ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME 3Q; CHROMOSOME DISORDER; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; COHORT ANALYSIS; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 79952344598     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-93     Document Type: Article

References (49)

1. Maione P, et al. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006, 11:274-84. 3, 10.1634/theoncologist.11-3-274, 16549812.
2. Morgan T, et al. Molecular profiling of Giant Cell Tumour of Bone and Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor kB. American Journal of Pathology 2005, 167:117-28. 10.1016/S0002-9440(10)62959-8, 1603441, 15972958.
3. Weiss MM, et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 2004, 26:307-17. 5-6.
4. Krypuy M, et al. High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007, 7. 168 PMID 17764544, 10.1186/1471-2407-7-168, 2025602, 17764544.
5. Krypuy M, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6. 295 PMID 17184525, 10.1186/1471-2407-6-295, 1769510, 17184525.
6. Smyth G. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology 2004, Article 3.
7. Smyth G, et al. The use of with-in array replicate spots for assessing expression in microarray experiments. Bioinformatics 2005, 2067.
8. Olshen A, et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004, 5:557-72. 10.1093/biostatistics/kxh008, 15475419.
9. Petersen I, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 1997, 57:2331-5. 12.
10. Bjorkqvist A, et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 1998, 22:79-82. 1, 10.1002/(SICI)1098-2264(199805)22:1<79::AID-GCC11>3.0.CO;2-D, 9591638.
11. Pei J, et al. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 2001, 31:282-87. 3, 10.1002/gcc.1145, 11391799.
12. Massion P, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridisation: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002, 62:3636-40. 13.
13. Massion P, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004, 170:1088-94. 10, 10.1164/rccm.200404-487OC, 15317667.
14. Kim T, et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 2005, 11:8235-42. 23, 10.1158/1078-0432.CCR-05-1157, 16322280.
15. Tonon G, et al. High-resolution genomic profiles of human lung cancer. Proc Nat Ac Science USA 2005, 9625-30.
16. Garnis C, et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006, 118:1556-64. 10.1002/ijc.21491, 16187286.
17. Graff J, Zimmer S. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clinical and Experimental Metastasis 2003, 20:265-73. 10.1023/A:1022943419011, 12741684.
18. Bilanges B, Stokoe D. Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 2007, 5973-5990. 10.1038/sj.onc.1210431, 17404576.
19. Sahin AA, et al. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer 1990, 65:530-7. 3, 10.1002/1097-0142(19900201)65:3<530::AID-CNCR2820650325>3.0.CO;2-6, 2153432.
20. Granone P, et al. DNA flow cytometric analysis in patients with operable non-small cell lung carcinoma. Eur J Cardiothorac Surg 1993, 7:351-5. 7, 10.1016/1010-7940(93)90065-J, 8396951.
21. Kasprzyk M, et al. Prognostic value of DNA ploidy: 5-year follow-up of patients with resectable squamous cell carcinoma (SCC) of the lung. Lung Cancer 2006, 51:201-6. 2, 10.1016/j.lungcan.2005.10.014, 16375987.
22. Choi H, et al. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Human Pathology 2002, 33:158-64. 2, 10.1053/hupa.2002.30722, 11957139.
23. Barbieri C, Barton C, Pietenpol J. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. The journal of biological chemistry 2003, 51:51408-14.
24. Glickman J, et al. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Human Pathology 2001, 32:1157-65. 11, 10.1053/hupa.2001.28951, 11727253.
25. Di Como C, et al. p63 expression profiles in human normal and tumour tissues. Clin Cancer Res 2002, 8:494-501. 2.
26. Pruneri G, et al. p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 2002, 82:1327-34. 10.
27. Massion P, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003, 63:7113-21. 21.
28. Au N, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004, 12:240-47. 3.
29. Van Cutsem E, Nowacki M, Lang I. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial. J Clin Pathol 2007, 25. 164s abstr 4000.
30. Thurfjell N, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004, 25:27-35. 1.
31. Nylander K, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002, 198:417-27. 4, 10.1002/path.1231, 12434410.
32. De Young MP, et al. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 2006, 66:9362-8. 19, 10.1158/0008-5472.CAN-06-1619, 17018588.
33. Ebert E, et al. Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997, 421:259-65.
34. Werle B, et al. Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep 2006, 16:647-55. 4.
35. Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-51. 21, 10.1200/JCO.2007.15.0375, 18506025.
36. Takahashi T, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-4. 4929, 10.1126/science.2554494, 2554494.
37. Sekido Y, Fong K, Minna J. Molecular biology of lung cancer. [book auth.] V DeVita, S Hellman and S Rosenberg. Cancer - principles and practice of oncology. s.l 2001, 1:917-25. Lippincott Williams & Wilkins.
38. Pao W, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PloS Med 2005, 2:c73. 3.
39. Peeters M, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009, 115:1544-54. 7, 10.1002/cncr.24088, 19189371.
40. Bokemeyer C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-71. 5, 10.1200/JCO.2008.20.8397, 19114683.
41. Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-34. 10, 10.1200/JCO.2007.14.7116, 18316791.
42. Schmid RS, et al. NCAM stimulates the Ras-MAPK pathway and CREB phosphorylation in neuronal cells. J Neurobiol 1999, 38:542-58. 4, 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.0.CO;2-1, 10084688.
43. Son H, et al. Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. Biochem Biophys Res Commun 2002, 298:262-8. 2, 10.1016/S0006-291X(02)02453-1, 12387826.
44. Ramaswamy S, et al. A molecular signature of metastasis in primary solid tumours. Nature Genetics 2003, 33:49-54. 10.1038/ng1060, 12469122.
45. Weigelt B, et al. Gene expression profiles of primary breast tumours maintained in distant metastases. Proc Nat Acad Sciences USA 2003, 100:15901-05. 26.
46. Akervall J, et al. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003, 9:1750-5. 5.
47. Hu Y, et al. Identification and functional characterization of a novel human Misshapen/Nck interacting kinase-related kinase, hMINK-beta. J Biol Chem 2004, 54387-54397. 10.1074/jbc.M404497200, 15469942.
48. Oh J, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800. 10.1016/S0092-8674(01)00597-9, 11747814.
49. Chang HC, Cho CY, Hung WC. Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 2007, 98:169-73. 2, 10.1111/j.1349-7006.2006.00367.x, 17233834.